Skip to main content
. 2020 Dec 30;15(12):e0244183. doi: 10.1371/journal.pone.0244183

Fig 1.

Fig 1

A. Proportion of nAMD patients by treatment status group (%). N, total number of patients; nAMD, neovascular age-related macular degeneration. B. Duration of prior ranibizumab treatment (N = 16,167). N, total number of patients; n, number of patients; nAMD, neovascular age-related macular degeneration.